SEC Tracker
Get the app

Myriad Genetics MYGN

Myriad Genetics Q1 FY24: revenue $202.2M; diluted EPS −$0.29

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Myriad Genetics reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$202.2MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$26.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$0.29No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$96.9MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations−$18.6MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Myriad Genetics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2835 and related industry codes: the same peer list as the financial tables.

  1. Kura Oncology KURA public float $496M, Jun 30, 2025
  2. KalVista Pharmaceuticals KALV public float $499M, Jun 30, 2025
  3. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025
  4. Arvinas ARVN public float $469M, Jun 30, 2025
  5. aTYR PHARMA ATYR public float $464M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.